Our study of 852 solid organ transplantations from HCV NAT-positive allografts into HCV seronegative recipients showed minimal impact on graft survival, rejection and adverse events. Furthermore, no patient deaths were related to the transmission of HCV, and a high rate of SVR12 was attained due to treatment with DAAs. These results suggest that transplanting organs from HCV viraemic allografts to seronegative recipients could become standard practice for patients who do not have contraindications to DAAs, as this can potentially help to alleviate organ donor shortage.
This material is based on work supported by the Center for Innovations in Quality, Effectiveness and Safety (CIN 13–413), Michael E. DeBakey VA Medical Center, Houston, TX. The supporting body played no part in the literature search, determination of study eligibility, interpretation of findings, or preparation of the manuscript for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.
Guarantor of the article
Data Availability Statement
Data available in article supplementary material.
Aliment Pharmacol Ther. 2021;54(5):571-582. © 2021 Blackwell Publishing